1
TITLE: Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
AUTHORS: Pérol, M; Pavlakis, N; Levchenko, E; Platania, M; Oliveira, J; Novello, S; Chiari, R; Moran, T; Mitry, E; Nüesch, E; Liu, T; Balas, B; Konopa, K; Peters, S;
PUBLISHED: 2019, SOURCE: Lung Cancer, VOLUME: 138
INDEXED IN: Scopus